Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2019

View Archived Issues

Safety and efficacy of autologous gene therapy after busulfan conditioning in infants with SCID-X1

Pharmacological modulation of sigma 2 receptor shows in vivo neuroprotective effect after TBI

Development of a new animal model of acute-on-chronic liver failure

TCF20 deficiency tied to liver fibrosis in animal models

Trigger region found for absence epileptic seizures

Discovery and optimization of novel STING agonist for the treatment of cancer

UCB-9260 demonstrates promising activity in TNF-alpha-driven mouse model

First patient enrolled in proof-of-concept study of ATH-3G10 in heart failure

FDA lifts partial clinical hold on phase I study of XmAb-14045

Phase IIa study of BIV-201 in refractory ascites meets primary objectives

Preclinical results presented for Ad5-3M in the treatment of solid and disseminated tumors

Gel-B prevents hepatic steatosis in HFD-induced NAFLD in vivo

Soluble MAdCAM-1 as a novel marker of endothelial activation in decompensated cirrhosis

Exonate presents SRPK1 inhibitor EXN-407

Innovatives Molecules describes new antiviral compounds

FORMA Therapeutics identifies new histone deacetylase 6 inhibitors

New phase II trial investigates BPN-14770 in early Alzheimer's disease

FDA approves Dengvaxia for prevention of dengue infection in endemic areas

Shanghai Institute of Materia Medica discloses new antibacterials

Bristol-Myers Squibb patents IDO-1 inhibitors

Merck & Co. describes new LRRK2 inhibitors

MCT 4 lactate transporter inhibitor AZD-0095 targets immunosuppression in tumors

NexImmune and MMRF partner to advance NEXI-002 for multiple myeloma

Genkyotex reports topline phase II data for GKT-831 in primary biliary cholangitis

FDA issues complete response letter for HTX-011 for postoperative pain

Checkpoint Therapeutics reports interim data from phase I trial of cosibelimab

FDA approves Mavyret for pediatric patients with HCV

European Commission approves Skyrizi for plaque psoriasis

Phase I study of CVN-424 for Parkinson's demonstrates safety in healthy subjects

Kalydeco approved in U.S. for infants from 6 months with cystic fibrosis

FDA issues complete response letter for Contepo for complicated urinary tract infections

3-V Biosciences initiates phase II trial of TVB-2640 in NASH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...